Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
With a market cap of 16 million. 17 %notifiable holdings mostly Nigel and individuals, I doubt there would be any resistance to honest Dan. Nobody has a big enough holding to defend. Although with a relatively low 180 million shares it could drive the sp quite a bit higher if there were more than 1 determined party, which seems to be Nigel's aim. Could get quite heated
RNS this morning or no RNS, big moves up today as momentum moves towards the big news.
Bedhead, Nuvec has been rigorously tested against Lipids and has proven to be superior in every test, so we know that Nuvec is by far the better option, which is why it could become a mainstream delivery system. One of the remarks that came out of one of Nigels recent interviews was that Nuvec is now being taken "seriously". What bothers me is that any sign that Nuvec is gaining traction is almost bound to see it being taken over as the potential if proven will be just too great for a larger pharma not to see the potential to make a killing by taking over N4 in its early stages. A takeover would obviously be at a large premium to today`s price but compared to the longer term potential it would be better for investors if Nigel resisted an offer until realistic value was seen in the price.
Not only have they positioned themselves directly in the path of a global pandemic that’s been fought hard with an RNA system, they’ve been doing this for several years so in theory have a competitive advantage to the companies trying to develop a novel system that’s non-lipid that’ll overcome all the existing issues.
Cancer therapeutics is obviously the icing on the cake but ultimately our business model is about taking collaborations to the next stage, that generates income and it isn’t affected by the outcome of the licensing deal, if it works we generate more income, if it fails we lose nothing.
There’s risks, possible delays and possible placings needed but no-one can argue that it couldn’t eventually make that billion pound valuation. Good luck
Nuvec for Vaccine delivery is exciting but what could it be worth for delivery of cancer drugs into the cells?
I’d rather be in than out.
Very happy to top up my position here.
Just as SP Angel quote. "at the right place at the right time and not by luck, but by design"
The lucky ones here are us as investors. Really starting to pan out well for us now.
181000000 shares x £5.20 ish = £1Billlion M/C
You never know!
I Read the directors talk sp angel article…..
I really believe N4P are on the cusp of vaccine delivery with nuvec, both injection and oral delivery. These two pharmas involved with the MTAs are obviously extremely interested and it seems to me with Nigel saying more mtas on the way vaccine developers will want in on licensing agreements if Nuvec proves to be superior.
N4P seem super confident Nuvec will be a game changing delivery system.
Exciting times to be a holder going into commercial activity.
Patience will hopefully pay off. Maybe once a flow of positive newsflow starts …patents, more mtas and multiple licensing agreements this could absolutely rocket potentially.
What could the market cap of this company go to if we get huge licensing agreements? Are we talking 10X or 20x current SP?
Could we eventually have a Billion £ company on our hands if every vaccine developer wanted in on nuvec!
Why not? I’m certainly holding.
Right place Right time for N4P investors
Love this Homer hahahahaha.
Come on Nigel. Be the top bloke we all know you are.
Brilliant Kris. Love these posts
I phoned Nigel earlier. He was going to send me over the RNS so I could check it and proof it before releasing in the morning.
I’ve got to be a douchebag once more because I really will kick myself tomorrow morning if I don’t get this in…
I, smell, a 7:30, RNS, tomorrow, morning.
Hold. Tight. Riders.
Odd to retweet now an article that has been about for months. Are the company prone to letting out hints like this ?
I think there may be a hint in the article N4pharma just tweeted , as to who we may be collaborating with or in talks with.
https://www.bbc.co.uk/news/health-57553602
The section regarding Janssen sounded like it could have potential links to a novel silica nanoparticle delivery system...
'The pharmaceutical giant would not say if this was connected to coronavirus or other infectious diseases, but a spokesperson said the research was part of a deep focus on "exploring novel technology that has the potential to ease distribution, administration and compliance" of future vaccines.'